Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
11 févr. 2019 08h00 HE
|
Allakos Inc.
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU...
Allakos to Host Investor Day on February 19 in New York City
04 févr. 2019 08h00 HE
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
29 janv. 2019 08h00 HE
|
Allakos Inc.
-- 82% (9 of 11) response rate in patients with cholinergic urticaria ---- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE...
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
07 janv. 2019 08h00 HE
|
Allakos Inc.
-- 12 of 13 (92%) patients achieved a complete response -- -- Results from 3 additional cohorts expected in the first quarter of 2019 -- REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) --...
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
08 nov. 2018 16h01 HE
|
Allakos Inc.
-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the...
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
08 oct. 2018 08h00 HE
|
Allakos Inc.
SAN CARLOS, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Second Quarter 2018 Financial Results
29 août 2018 16h01 HE
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 juil. 2018 08h00 HE
|
Allakos Inc.
SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
Allakos Announces Pricing of Initial Public Offering
19 juil. 2018 07h00 HE
|
Allakos Inc.
SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress
05 mars 2018 09h45 HE
|
Allakos
-- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as...